At 10.0% CAGR, North America Embolization Devices Market is Projected to be Worth US$ 2,404.42 Million by 2031, Says Business Market Insights

According to Business Market Insights' research, the North America embolization devices market was valued at US$ 1,242.60 million in 2024 and is expected to reach US$ 2,404.42 million by 2031, registering a CAGR of 10.0% from 2025 to 2031. Rising prevalence of clinical conditions and transforming embolization through clinical innovation are among the critical factors attributed to the North America embolization devices market expansion.

Vascular diseases, including peripheral artery disease (PAD), aneurysms, and arteriovenous malformations (AVMs), are becoming more prevalent globally. These conditions have become particularly common among geriatric populations and individuals exposed to lifestyle-related risk factors. Peripheral vascular disease (PVD) consists of PAD and venous disease. According to the article "Income-Related Peripheral Artery Disease Treatment," published in the National Library of Medicine in 2022, more than 200 million people worldwide suffer from PAD, and ~10% of the affected people in Western Europe and North America were aged 50 years and above. The prevalence of PVD ranges from 3% in patients aged >55 years and 11% in patients aged >65 years to 20% in patients aged >75.

The cases of neurovascular conditions such as strokes and brain aneurysms are also on the rise across the world. As per the Brain Aneurysm Foundation estimates, 6.8 million people in the US have an unruptured brain aneurysm. Each year, nearly 30,000 Americans suffer a brain aneurysm rupture, often requiring immediate intervention through embolization techniques. Almost 500,000 people die worldwide due to brain aneurysms each year. Brain aneurysms are most prevalent in people from the age group of 35-60, and most aneurysms develop after the age of 40. Additionally, ruptured brain aneurysms account for 3-5% of all new strokes.

As per the World Health Organization (WHO), postpartum hemorrhage is the foremost cause of maternal mortality globally. About 14 million women experience this each year, resulting in about 70,000 maternal deaths worldwide. Additionally, as per the Institute for Functional Medicine, the prevalence of uterine fibroids has increased a predictable 78.82% in the past 30 decades, from 126.41 million to 226.05 million cases.

These clinical conditions can be effectively treated using embolization devices as these tools are designed to block abnormal or excessive blood flow within blood vessels, and this technique is preferred due to its minimally invasive nature. Embolization involves the deliberate occlusion of blood vessels to treat conditions such as aneurysms, postpartum hemorrhage, uterine fibroids, and certain types of tumors. Embolization is used to control severe bleeding after childbirth when conventional methods are ineffective, as well as blocks the blood supply to fibroids, causing them to shrink and symptoms to improve. Thus, the escalating burden of these conditions fuels the growth of the embolization devices market.

On the contrary, complications arising during or after embolization hamper the growth of North America embolization devices market.

Based on type, the North America embolization devices market is segmented into embolization coils, plugs, beads, glues, and others. The embolization coils segment held 61.2% share of the North America embolization devices market in 2024, amassing US$ 760.46 million. It is projected to garner US$ 1,506.41 million by 2031 to expand at 10.4% CAGR during 2025-2031. The embolization coils segment is further subsegmented into central application and peripheral application.

Based on application, the North America embolization devices market is segmented into neurology, peripheral vascular disease, oncology, urology, and others. The neurology segment held 41.1% share of the North America embolization devices market in 2024, amassing US$ 510.23 million. It is projected to garner US$ 1,024.92 million by 2031 to expand at 10.6% CAGR during 2025-2031.

Based on end user, the North America embolization devices market is segmented into hospitals, ambulatory centers, and others. The hospitals segment held 56.0% share of the North America embolization devices market in 2024, amassing US$ 696.36 million. It is projected to garner US$ 1,388.61 million by 2031 to expand at 10.5% CAGR during 2025-2031.

Based on country, the North America embolization devices market is segmented into the US, Canada, and Mexico. The US held 82.5% share of North America embolization devices market in 2024, amassing US$ 1,025.38 million. It is projected to garner US$ 2,002.30 million by 2031 to expand at 10.2% CAGR during 2025-2031.

Key players operating in the embolization devices market are Medtronic Plc; Cook Medical Holdings LLC; Stryker Corp; Boston Scientific Corp; Terumo Corp; Johnson & Johnson; Abbott Laboratories; NeuroSafe Medical Co. Ltd; Wallaby Medical; Sirtex Medical Ltd; GEM srl; Penumbra Inc.; Balt; Lepu Medical Technology Beijing Co Ltd; INVAMED; Meril Life Sciences Pvt Ltd; Merit Medical Systems Inc; and Lifetech Scientific Corp, among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com